The STIM-ADHF Study
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT05313438 |
Recruitment Status :
Recruiting
First Posted : April 6, 2022
Last Update Posted : September 26, 2022
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Acute Decompensated Heart Failure | Device: CPNS Therapy | Not Applicable |
Study Type : | Interventional (Clinical Trial) |
Estimated Enrollment : | 50 participants |
Allocation: | N/A |
Intervention Model: | Single Group Assignment |
Masking: | None (Open Label) |
Primary Purpose: | Treatment |
Official Title: | Cardiac Pulmonary Nerve STIMulation in Acute Decompensated Heart Failure |
Actual Study Start Date : | May 10, 2022 |
Estimated Primary Completion Date : | April 2023 |
Estimated Study Completion Date : | May 2023 |

Arm | Intervention/treatment |
---|---|
Experimental: CPNS Therapy
Endovascular stimulation of the cardiac autonomic nerves in addition to standard of care.
|
Device: CPNS Therapy
Endovascular stimulation of the cardiac autonomic nerves in addition to standard of care |
- Occurrence of related adverse events [ Time Frame: Enrolment to 30 Days post hospital discharge ]The following measures will be characterized in all enrolled subjects: occurrence of all procedure, device and therapy related adverse events, serious adverse events and deaths

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Admitted to the hospital or planned to be admitted with a principal diagnosis of acute decompensated heart failure
- BMI adjusted BNP ≥ 500 pg/mL or NT-proBNP ≥ 2000 pg/mL
- LVEF ≤ 50%
- At least one sign/symptom of fluid overload
- At least one of the following:
- Inadequate diuretic response
- At least one sign or symptom of low perfusion
Exclusion Criteria:
- Received an inotrope during current hospitalization
- Requires mechanical support
- Cardiogenic shock or impending cardiogenic shock
- Multi-organ failure
- Systolic blood pressure < 80mmHg or > 140mmHg
- Symptomatic hypotension
- eGFR < 25 mL/min/1.732
- Severe hepatic disease

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT05313438
Contact: Michelle Kennefick | 6516331388 | clinical@cardionomicinc.com |
Hungary | |
Semmelweis University, Heart and Vascular Center | Recruiting |
Budapest, Hungary | |
Hearth Faculty of Medicine, University of Pécs | Recruiting |
Pécs, Hungary | |
Szegedi Tudományegyetem ÁOK | Recruiting |
Szeged, Hungary | |
Poland | |
American Heart of Poland | Recruiting |
Bielsko Biala, Poland | |
Slovakia | |
Stredoslovenský Ústav srdcových a Cievnych Chorȏb, a.s. | Recruiting |
Banská Bystrica, Slovakia, 97401 | |
CINRE s.r.o | Recruiting |
Bratislava, Slovakia |
Responsible Party: | Cardionomic Inc. |
ClinicalTrials.gov Identifier: | NCT05313438 |
Other Study ID Numbers: |
CLN-1108-001 |
First Posted: | April 6, 2022 Key Record Dates |
Last Update Posted: | September 26, 2022 |
Last Verified: | September 2022 |
Studies a U.S. FDA-regulated Drug Product: | No |
Studies a U.S. FDA-regulated Device Product: | Yes |
Device Product Not Approved or Cleared by U.S. FDA: | Yes |
Product Manufactured in and Exported from the U.S.: | Yes |
Neurostimulation Contractility Right Pulmonary Artery |
Heart Failure Heart Diseases Cardiovascular Diseases |